Biology is becoming a proving ground for frontier AI labs. OpenAI acquired Orchestra Bio yesterday. Anthropic is expanding in life sciences. Google has Co-Scientist. And we just introduced X-Scientist at Xaira. My takeaway from building it: the hard part is sustaining scientific judgment across a long investigation. The harness must preserve evidence across sessions, interpret predictions in biological context, recover from failed workflows, and choose informative experiments despite noisy, delayed feedback. Crucially, “the code ran” and “the biology is supported” are very different milestones. With X-Scientist, we’re connecting scientific orchestration, specialized biological models, verification, and autonomous research with experimental feedback as the next step toward a self-improving virtual drug hunter.

Moderna/Merck just ran a 1,137-patient Phase 3 trial where every single dose was unique to that patient's tumor. It worked. The pipeline: surgical resection → whole exome + RNA sequencing → ML neoantigen ranking → mRNA encoding up to 34 patient-specific targets → manufactured and shipped in 8 weeks. One drug, different sequence for every patient. The ML step is worth to note: the algorithm ingests WES + RNA-seq to identify somatic mutations, then predicts which of those will actually be immunogenic, ie, displayed on tumor cell surface and trigger a T-cell response. It's designed to keep learning from accumulated clinical and immunogenicity data across patients, not just per-patient. INTerpath-001 (Stage IIB-IV resected melanoma, 2:1 randomized): combination with pembrolizumab beat Keytruda alone on both primary (RFS) and key secondary (DMFS) at interim. Phase 2b at ASCO 2026 showed 49% reduction in recurrence/death, 59% in distant metastasis/death at 5 years. Phase 3 confirmed both. What this validates: — tumor-specific neoantigen prediction by ML works in a blinded trial at scale — 8-week personalized mRNA manufacturing is operationally real — effect is additive on PD-1 blockade, not redundant This is first positive Ph3 for individualized neoantigen therapy. First positive Ph3 for any mRNA cancer therapeutic. What a great time to live in!! This is the best time for AI & biotech!